[ET Net News Agency, 22 August 2024] Citi lowered the target price for CSPC Pharma
(01093) to HKD10 from HKD13 and maintained the "buy" rating.
The research house said it cuts FY24/25/26 revenue forecasts by 9%/17%/22% to factor in
oncology sales decline and slower than expected innovative sales. (rc)